681 related articles for article (PubMed ID: 28169118)
1. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Winquist E;
Clin Oncol (R Coll Radiol); 2017 Jun; 29(6):348-355. PubMed ID: 28169118
[TBL] [Abstract][Full Text] [Related]
2. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
[TBL] [Abstract][Full Text] [Related]
3. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M
Cancer Treat Rev; 2016 Mar; 44():61-73. PubMed ID: 26907461
[TBL] [Abstract][Full Text] [Related]
4. The role of bone-targeted therapies for prostate cancer in 2017.
Traboulsi SL; Saad F
Curr Opin Support Palliat Care; 2017 Sep; 11(3):216-224. PubMed ID: 28644302
[TBL] [Abstract][Full Text] [Related]
5. Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.
Miller K; Steger GG; Niepel D; Lüftner D
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):461-472. PubMed ID: 29988100
[TBL] [Abstract][Full Text] [Related]
6. Management of bone metastases in prostate cancer: a review.
Bienz M; Saad F
Curr Opin Support Palliat Care; 2015 Sep; 9(3):261-7. PubMed ID: 26262831
[TBL] [Abstract][Full Text] [Related]
7. Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.
Graff JN; Beer TM
Oncology (Williston Park); 2015 Jun; 29(6):416-23. PubMed ID: 26091674
[TBL] [Abstract][Full Text] [Related]
8. Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer.
Saylor PJ
Asian J Androl; 2014; 16(3):341-7. PubMed ID: 24435057
[TBL] [Abstract][Full Text] [Related]
9. The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer.
Saad F; Sternberg CN; Mulders PFA; Niepel D; Tombal BF
Cancer Treat Rev; 2018 Jul; 68():25-37. PubMed ID: 29787892
[TBL] [Abstract][Full Text] [Related]
10. Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.
Dorff TB; Agarwal N
Asian J Androl; 2018; 20(3):215-220. PubMed ID: 29553053
[TBL] [Abstract][Full Text] [Related]
11. Targeting bone metastases in prostate cancer: improving clinical outcome.
Body JJ; Casimiro S; Costa L
Nat Rev Urol; 2015 Jun; 12(6):340-56. PubMed ID: 26119830
[TBL] [Abstract][Full Text] [Related]
12. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
[TBL] [Abstract][Full Text] [Related]
13. Pathologic fracture in patients with metastatic prostate cancer.
Gartrell BA; Saad F
Curr Opin Urol; 2014 Nov; 24(6):595-600. PubMed ID: 25166424
[TBL] [Abstract][Full Text] [Related]
14. Bone health and prostate cancer.
Saylor PJ; Smith MR
Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):20-7. PubMed ID: 19901958
[TBL] [Abstract][Full Text] [Related]
15. Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis.
Hayes AR; Brungs D; Pavlakis N
PLoS One; 2018; 13(1):e0191455. PubMed ID: 29370211
[TBL] [Abstract][Full Text] [Related]
16. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Fizazi K; Carducci M; Smith M; Damião R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
[TBL] [Abstract][Full Text] [Related]
17. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
Gartrell BA; Coleman RE; Fizazi K; Miller K; Saad F; Sternberg CN; Galsky MD
Eur Urol; 2014 Feb; 65(2):278-86. PubMed ID: 23706567
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer.
Dellis A; Papatsoris A
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):5-10. PubMed ID: 26588857
[TBL] [Abstract][Full Text] [Related]
19. Emerging therapies to prevent skeletal morbidity in men with prostate cancer.
Saylor PJ; Lee RJ; Smith MR
J Clin Oncol; 2011 Sep; 29(27):3705-14. PubMed ID: 21860001
[TBL] [Abstract][Full Text] [Related]
20. Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Tomlinson GA; Winquist E
Ann Intern Med; 2017 Sep; 167(5):341-350. PubMed ID: 28785760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
